EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose

Alan Jardine, Steven K Burke, Wenli Luo, Todd Minga, Mark J Sarnak, Wolfgang C Winkelmayer, Rajiv Agarwal, Glenn M Chertow, Kai-Uwe Eckardt, Mark J Koury

Hemodialysis International · 2026

DOI: 10.1111/hdi.70034 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Hemodialysis International, 2026. Verfasst von Alan Jardine und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Darbepoetin alfa, Anemia, Renal Insufficiency, Chronic, Hematinics. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Akebia Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies are sought for patients requiring high ESA doses. Phase 3 INNO 2 VATE trials in patients with dialysis‐dependent CKD (DD‐CKD) demonstrated vadadustat's noninferiority compared with darbepoetin alfa. To determine vadadustat's potential to treat anemia, including in patients requiring high ESA doses, its safety and efficacy were compared with those of darbepoetin alfa across prespecified baseline ESA dose subgroups in the prevalent DD‐CKD INNO 2 VATE trial.

Methods

We compared the safety and efficacy of vadadustat versus darbepoetin alfa across prespecified baseline ESA dose subgroups (low [≤ 90 U/kg/week], intermediate [> 90 and < 300 U/kg/week], or high [≥ 300 U/kg/week]) in the INNO 2 VATE prevalent trial. The primary safety endpoint was time to first adjudicated major adverse cardiovascular event (MACE). Primary and secondary efficacy endpoints were mean hemoglobin level change from baseline at weeks 24–36 and weeks 40–52, respectively.

Findings

Compared with darbepoetin alfa, first MACE hazard ratios for vadadustat were 0.99 (95% CI, 0.81–1.23), 0.93 (95% CI, 0.74–1.18), and 0.62 (95% CI, 0.34–1.14) for low, intermediate, and high baseline ESA dose subgroups, respectively (interaction p = 0.92). Vadadustat was noninferior to darbepoetin alfa in hemoglobin change from baseline to primary evaluation period, with mean differences (vadadustat–darbepoetin alfa) of −0.10 g/dL (95% CI, −0.19 to −0.02), −0.20 g/dL (95% CI, −0.30 to −0.09), and −0.39 g/dL (95% CI, −0.67 to −0.11) for low, intermediate, and high ESA dose subgroups, respectively.

Discussion

Comparing safety and efficacy by baseline ESA dose among patients with CKD on maintenance dialysis, vadadustat was noninferior to darbepoetin alfa for all ESA dose subgroups, including patients with high baseline ESA requirements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Darbepoetin alfaAnemiaRenal Insufficiency, ChronicHematinicsRenal DialysisGlycineHumansMaleFemaleMiddle AgedAgedPicolinic Acids

Stichwörter der Autor:innen

CKDESAHIF‐PHIanemiadialysis

Substanzen

Darbepoetin alfaHematinicsGlycinevadadustatPicolinic Acids

Autor:innen und Institutionen

  • Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Akebia Therapeutics, Inc., Cambridge, Massachusetts, USA.
  • Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
  • Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Medicine, and Richard L. Roudebush Veterans Administration Medical Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Palo Alto, California, USA.

Förderung

  • Akebia Therapeutics

Zitieren

APA

Jardine, A., Burke, S. K., Luo, W., Minga, T., Sarnak, M. J., Winkelmayer, W. C., Agarwal, R., Chertow, G. M., Eckardt, K. U., & Koury, M. J. (2026). Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose. Hemodialysis International. https://doi.org/10.1111/hdi.70034

Vancouver

Jardine A, Burke SK, Luo W, Minga T, Sarnak MJ, Winkelmayer WC, et al. Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose. Hemodialysis International. 2026. doi:10.1111/hdi.70034

BibTeX
@article{Jardine2026,
  author = {Jardine, Alan and Burke, Steven K and Luo, Wenli and Minga, Todd and Sarnak, Mark J and Winkelmayer, Wolfgang C and Agarwal, Rajiv and Chertow, Glenn M and Eckardt, Kai-Uwe and Koury, Mark J},
  title = {Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose},
  journal = {Hemodialysis International},
  year = {2026},
  doi = {10.1111/hdi.70034}
}
Kostenlos starten →